GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Interest Coverage

Island Pharmaceuticals (ASX:ILA) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Island Pharmaceuticals's Operating Income for the six months ended in Dec. 2024 was A$-1.60 Mil. Island Pharmaceuticals's Interest Expense for the six months ended in Dec. 2024 was A$-0.03 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Island Pharmaceuticals's Interest Coverage or its related term are showing as below:


ASX:ILA's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Island Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Island Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Island Pharmaceuticals Interest Coverage Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Interest Coverage
No Debt No Debt - -

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Interest Coverage Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Island Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, Island Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Island Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's Interest Coverage falls into.


;
;

Island Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Island Pharmaceuticals's Interest Coverage for the fiscal year that ended in Jun. 2024 is calculated as

Here, for the fiscal year that ended in Jun. 2024, Island Pharmaceuticals's Interest Expense was A$-0.05 Mil. Its Operating Income was A$-2.87 Mil. And its Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.

Island Pharmaceuticals did not have earnings to cover the interest expense.

Island Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, Island Pharmaceuticals's Interest Expense was A$-0.03 Mil. Its Operating Income was A$-1.60 Mil. And its Long-Term Debt & Capital Lease Obligation was A$0.00 Mil.

Island Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Island Pharmaceuticals  (ASX:ILA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Island Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Island Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.

Island Pharmaceuticals Headlines

No Headlines